New research in JACC: Cardiovascular Interventions suggests improved collaborations between cardiologists and neurologists could help TAVR patients live longer after a periprocedural stroke. 

Pulmonary artery denervation may offer a new therapy option for this difficult-to-treat population.

The UNIVERSAL Trial, one of the largest multicenter randomized trials comparing ultrasound with fluoroscopic guidance vs. fluoroscopic guidance alone, found there was no reduction in major vascular access complications. 

Progestin-only products may be a "safer alternative" for this patient population, according to a new analysis. 

A new consensus statement from the Society of Cardiovascular Computed Tomography emphasized the increasing importance of CCTA among interventional cardiologists. It is no longer seen as “a mere diagnostic tool," the group observed. 

A two-medication strategy after CABG surgery reduces the risk that grafts will fail, but it also increases the risk of serious bleeding. As one surgeon said, "the benefit comes at a price.”

The FDA has had a busy month, overseeing the recall of nearly 88,000 implantable cardiac devices, juggling the continued rise of monkeypox cases in the United States and maintaining an active Breakthrough Devices program. This rundown covers some of the agency's biggest moves during that time. 

A new meta-analysis of 28 different studies confirmed that robotic-assisted radical nephrectomy with IVC thrombectomy is a safe treatment option for kidney cancer.